How to appeal an Aetna inflammatory bowel disease (crohn's + uc) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for inflammatory bowel disease (crohn's + uc)

Cited policy: Aetna CPB on Stelara (Ustekinumab) for Crohn's + UC

Crohn's: moderate-severe disease, failure or intolerance of conventional therapy (steroids + immunomodulator) AND failure of >=1 anti-TNF OR contraindication. UC: moderate-severe, failure of conventional therapy AND failure of >=1 anti-TNF OR contraindication. IV induction weight-based then 90 mg SC q8wk. Reauth at 6 mo.

How Aetna denies inflammatory bowel disease (crohn's + uc) — and how to counter it

Where Aetna pushes back: 1) Must fail two anti-TNFs first; 2) Must try Entyvio before Stelara; 3) Investigational for biologic-naïve.

Counter-arguments that hold up: Stelara FDA-approved CD Sep 26, 2016 (UNITI-1/2 + IM-UNITI NEJM 2016;375:1946) and UC Oct 21, 2019 (UNIFI NEJM 2019;381:1201). SEAVUE (Sands Lancet 2022) — Stelara non-inferior to Humira in biologic-naïve CD with comparable safety. AGA CD 2020 + UC 2020 list ustekinumab as parallel first-line option. Primary anti-TNF non-response predicts second TNFi failure — class switch endorsed per AGA TDM 2017 (Feuerstein Gastro 2017;153:827).

What Aetna typically denies for inflammatory bowel disease (crohn's + uc)

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For inflammatory bowel disease (crohn's + uc), expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the inflammatory bowel disease (crohn's + uc) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira (adalimumab)
• Remicade (infliximab)
• Cimzia (CD only)
• Simponi (UC only)
• Stelara (ustekinumab)
• Skyrizi (risankizumab)

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.